A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB

被引：0
|
作者：
Ajani, J. A. [1 ]
Udrea, A. [2 ]
Sarosiek, T. [3 ]
Shenker, M. [4 ]
Morgan, C. [5 ]
Pikiel, J. [6 ]
Wojcik, E. [7 ]
Swinson, D. [8 ]
Joseph, M. [9 ]
Luft, A. [10 ]
Salek, T. [11 ]
Tournigand, C. [12 ]
Ferry, D. [13 ]
Zhang, Y. [13 ]
Long, A. [13 ]
Kuo, W-L. [13 ]
Gao, L. [13 ]
Kauh, J. [13 ]
Mansoor, W. [14 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA
[2] MedisProf SRL, Oncol, Cluj Napoca, Romania
[3] Magodent, Oncol, Warsaw, Poland
[4] Sf Nectarie SRL, Ctr Oncol, Craiova, Romania
[5] Velindre Canc Ctr, Oncol, Cardiff, S Glam, Wales
[6] COPERNICUS Podmiot Leczniczy, Oncol, Gdansk, Poland
[7] NZOZ Ctr Med HCP, Oncol, Poznan, Poland
[8] St James Univ Hosp, St Jamess Inst Oncol, Leeds, W Yorkshire, England
[9] New Cross Hosp, Deanesly Ctr, Wolverhampton, England
[10] Leningrad Reg Clin Hosp, Oncol, St Petersburg, Russia
[11] Narodny Onkol Ustav, Oncol, Bratislava, Slovakia
[12] CHU Henri Mondor, Oncol, Creteil, France
[13] Eli Lilly & Co, Oncol, Bridgewater, NJ USA
[14] NHS Fdn Trust, Christie Hosp, Manchester, Lancs, England
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
698P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Health-related quality-of-life (HRQoL) results from the FAST study, a phase 2 trial of epirubicin, oxaliplatin and capecitabine with or without IMAB362 in patients with advanced CLDN18.2+gastric (GA) and gastroesophageal junction (GEJ) adenocarcinoma.
    Morlock, Robert
    Turnbul, James
    Blahut, Steven
    Krukas-Hampel, Michelle R.
    Hawryluk, Emily
    Tureci, Ozlem
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer.
    Chao, Joseph
    Buxo, Elvira
    Cervantes, Andres
    Dayyani, Farshid
    Rocha Lima, Caio Max Sao Pedro
    Greil, Richard
    Van Laarhoven, Hanneke W. M.
    Lorenzen, Sylvie
    Heinemann, Volker
    Kischel, Roman
    Shitara, Kohei
    Lordick, Florian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE)
    Wilke, Hansjochen
    Van Cutsem, Eric
    Oh, Sang Cheul
    Bodoky, Gyorgy
    Shimada, Yasuhiro
    Hironaka, Shuichi
    Sugimoto, Naotoshi
    Lipatov, Oleg N.
    Kim, Tae-You
    Cunningham, David
    Ohtsu, Atsushi
    Rougier, Philippe
    Emig, Michael
    Carlesi, Roberto
    Chandrawansa, Kumari
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [34] A randomized phase II clinical trial evaluating the safety and efficacy of initial dose adjustment of zolbetuximab plus chemotherapy in patients with HER2-negative and CLDN18.2-positive unresectable advanced or recurrent gastric, gastroesophageal junction cancer or esophageal adenocarcinoma (GENTLE-Z).
    Okunaka, Mashiro
    Furuoka, Momoka
    Wakabayashi, Masashi
    Furuya, Hideki
    Bando, Hideaki
    Shitara, Kohei
    Nakayama, Izuma
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS504 - TPS504
  • [35] ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.
    Oh, Youn
    Chung, Hyun Cheol
    Im, Young Hyuck
    Yen, Chia Jui
    Chao, Yee
    Li, ZheZhen
    Wang, Xin
    Wang, Jin
    Li, Huiyan
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] A phase I/II study of FG-M108 plus capecitabine and oxaliplatin (CAPOX) as first-line (1L) treatment for patients with CLDN18.2+/HER2-advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Gong, J.
    Liu, F.
    Jin, Z.
    Zhang, M.
    Zhang, S.
    Zhang, Y.
    Liang, X.
    Li, Y.
    Yang, Y.
    Shen, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S892 - S892
  • [37] Safety and efficacy results from the phase I/IIa study of FG-M108 plus CAPOX as first-line (1L) treatment for patients with CLDN18.2+/HER2-locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Liu, Funan
    Gong, Jifang
    Jin, Zhaoyu
    Zhang, Miao
    Zhang, Shu
    Zhang, Yanqiao
    Liang, Xinjun
    Li, Yun
    Yang, Xiaochun
    Yang, Yaping
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Trastuzumab Deruxtecan (T-DXd) in Patients (Pts) With HER2-Positive Gastric Cancer (GC) or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Progressed On or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04, DG-04): A Randomized Phase 3 Study
    Shitara, Kohei
    Barlaskar, Ferdous
    Franke, Fabio A.
    Kawaguchi, Yoshinori
    Shen, Lin
    Kamio, Takahiro
    Meinhardt, Gerold
    Tabernero, Josep
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 95 - 95
  • [39] Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-gastric04, DG-04): A randomized phase III study
    Shitara, K.
    Seraj, J.
    Franke, F. A.
    Kawaguchi, Y.
    Shen, L.
    Kamio, T.
    Meinhardt, G.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1073 - S1073
  • [40] A Randomized, Double-Mask, Placebo-Controlled, Dose-Response, Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Diabetic Patients' Corneal Wounds Resulting From Epithelial Debridement During Vitrectomy
    Jeng, B. H.
    Sosne, G.
    Srivastava, S.
    Marcus, D. M.
    Gentile, R. C.
    Martin, L.
    Crockford, D.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
12345